Avigen Presenting at NYSSA 7th Annual Healthcare Conference Today

Avigen Presenting at NYSSA 7th Annual Healthcare Conference Today 


ALAMEDA, Calif., Nov. 18  /PRNewswire-FirstCall/ -- Avigen, Inc., , a leader in
the development of gene-based drugs for serious chronic diseases, announced that
its president and CEO, John Monahan, Ph.D., will make a presentation at the New
York Society of Securities Analysts 7th Annual Healthcare Conference in New York
City at 1:30 p.m. eastern time today, Tuesday, November 18, 2003.

Dr. Monahan will provide an overview of the company's proprietary gene delivery
technology and recent events in the company's primary product development
programs in hemophilia and Parkinson's disease, including the filing of an IND
for AV201, Avigen's ground breaking approach to the treatment of advanced
Parkinson's disease.

The presentation will be webcast live at
http://www.shareholder.com/avigen/medialist.cfm and through Avigen's web site,
http://www.avigen.com/. An archived version of the presentation will be
available through December 18, 2003.

About Avigen

Avigen, Inc., based in the San Francisco Bay Area, focuses on the development of
DNA-based drugs for serious chronic conditions. Avigen's proposed gene delivery
products are designed for direct administration to patients in order to achieve
expression of therapeutic proteins within the body. The company is actively
enrolling subjects in its clinical trial for Coagulin-B(R), Avigen's Factor IX
gene therapy product for hemophilia B, currently being conducted at the
Children's Hospital of Philadelphia and Stanford University Medical Center.
Patients or physicians who would like more information about enrollment criteria
and the study should contact the Clinical Development Department at  or call at
510-748-7379. Additional information on Avigen's proprietary gene delivery
products can be found at http://www.avigen.com/ 

DATASOURCE: Avigen, Inc.



CONTACT:  Lise Needham, Associate Director of Investor Relations of

Avigen, Inc., [phone], or 



Web site:  http://www.shareholder.com/avigen/medialist.cfm

Web site:  http://www.avigen.com/

Copyright